Key Takeaways
- Volume-led 20% revenue growth, but mix masks pricing: Total revenue hit ₹929 cr on 35% volume growth, yet a negative product mix of -17% absorbed most of the volume gain, leaving the underlying price recovery slow and uneven.
- Gross margin surged 690 bps on input cost relief: Gross margin reached 34.5%, driven by input cost stabilization, not by pricing power; management expects H2 margins in a similar range.
- Agrochemicals carried the quarter, non-agro shrank: Agrochemical revenue grew 27% YoY to ₹803 cr, while non-agrochemical fell 11% to ₹126 cr on lower demand, with no consistency expected.
- Full-year EBITDA margin guide held at 15-18%: Hitting that range requires H2 margins above 18-19%, a steep ask that rests entirely on the seasonal second-half uptick materializing.
- What to watch next quarter: Whether the H2 seasonal strength actually delivers the margin step-up needed to meet full-year guidance, and whether the slow price uptrend accelerates enough to narrow the volume-to-revenue gap.
Volume, Mix & the Pricing Puzzle
- Volume growth was broad-based: Total volume rose 35% YoY, with growth across all regions, driven by a global revival in demand and some recovery in prices from historically low levels.
- Product mix ate 17 percentage points of growth: Revenue growth of 19.6% broke down into volume +34.8%, FX +1.9%, and product mix -17%; management did not separately identify pure price impact.
- "Better pricing" means off the bottom, not up sequentially: Management clarified that pricing references recovery from historically low levels, not quarter-on-quarter improvement, and that the uptrend is slow.
- Mix explains the Q1-to-Q2 EBIT drop: Agrochemical EBIT fell ~₹100 cr QoQ on similar revenue because volume growth concentrated in lower-priced, lower-margin products; gross margin still improved because margins vary product-to-product with no standard relationship.
- Non-agrochemical margin paradox left unexplained: Volume growth has exceeded sales growth for 3-4 quarters, yet segmental margins improved; management attributed it to better product mix but declined to elaborate when pressed.
Bubna: "Mr. Rajdeep, you have touched the right point, and it is actually the product mix, which didn't occur to me, and this has occurred to you."
The Registration Moat & Tariff Immunity
- Registration is the structural barrier: Agrochemical products are not freely tradable; every product must be registered in each country, and the process is complicated, investment-intensive, time-consuming, and, in management's word, "boring."
- Tariff risk is blunted by the moat: Customers cannot simply switch sources based on tariff rates because only registration holders can supply a given product in a given country; management expects no substantial impact from US tariffs on H2 business.
- Few competitors have comparable breadth: While any registration holder can bid for a tender, few companies hold as wide a range of registrations across as many markets, limiting competitive pressure.
- The asset-light model insulates against manufacturing cycles: Manufacturers struggle to maintain operations in the off-season; Sharda's sourcing model avoids that fixed-cost burden and lets it flex across hundreds of products.
Bubna: "Every company who has the registration of that product in that country can bid for the tender. But there are not many people who have such a wide range of registrations and the registration process is a very complicated, investment-oriented, time-consuming and boring."
Agrochemical vs Non-Agrochemical Divergence
| Segment | Revenue (Q2 FY26) | YoY Growth | Driver |
|---|---|---|---|
| Agrochemical | ₹803 cr | ▲ 27% | Volume recovery across regions, slow price uptrend |
| Non-agrochemical | ₹126 cr | ▼ 11% | Demand variation; lower volume, no consistency expected |
- Non-agrochemical is made-to-order, not stocked: The conveyor belt business produces only against customer specifications, so demand softness translates directly into lower volumes with no inventory buffer.
- Non-agrochemical margin improvement despite the sales drop: Attributed to better product mix within the smaller revenue base; management declined to provide further detail when analysts noted the multi-quarter pattern.
- Europe agro growth normalized sharply: Europe agrochemical revenue grew 15% in Q2 FY26 versus 75% in the same quarter last year; management called 15% "very normal" and declined to comment further on the deceleration or the contrast with North America's strong growth.
Margin Bridge & the H2 Bet
- Gross margin expansion was the quarter's standout: Gross margin rose 690 bps YoY to 34.5% in Q2, and 660 bps to 35% in H1, driven entirely by input cost stabilization after a period of elevated raw material prices.
- H2 gross margins expected in a similar range: The second half benefits seasonally from the spring season with high demand, but management did not signal further expansion.
- The full-year EBITDA guide embeds a sharp H2 ramp: FY26 EBITDA margin is guided at 15-18%; with H1 already booked, H2 must deliver above 18-19% to land in that range, a level management has not yet demonstrated this year.
- Forex loss is notional, not operational: The ₹6.7 cr forex loss in Q2 relates to accounting realignment of foreign currency payables for product registration capex; actual impact occurs only on payment date, and management called it "not real."
- Euro strength is a tailwind: Sourcing is in dollars, major European sales are in euros; management welcomes a stronger euro and has seen instances of 1.25x and 1.3x.
Capex, Revenue Ambition & the Non-Speculation Stance
- Capex plan held at ₹450-500 cr for FY26: Backed by a strong pipeline, with spending directed at product registrations that deepen the competitive moat.
- Revenue could cross ₹5,000 cr this year: Management confirmed the possibility, and when asked about ₹5,200 cr, said "Yes, it can," but framed both as approximate, not commitments.
- ₹10,000 cr in 4-5 years is not on the table: Management declined to speculate, stating "We don't gamble and we don't speculate. It could happen. Nobody can predict."
- Forex and macro calls are outsourced, not owned: Management takes expert opinions but notes that experts also go wrong; the company does not build forecasts around currency or macro bets.
Bubna: "We don't speculate. We take opinions of the experts, and we find that many times the experts also go wrong. They are not fortune tellers."
Deflections & Unanswered Questions
- Europe agro deceleration: Why Europe agrochemical growth fell from 75% YoY to 15% YoY, and what diverged from North America's strong performance, drew "nothing specific that I can comment on."
- Negative realization in non-agrochemical: The multi-quarter pattern of volume growth exceeding sales growth, alongside improving margins, was met with "We will take offline this question."
- Q1-to-Q2 agrochemical EBIT drop: The ~₹100 cr decline on similar revenue was initially deflected, then attributed to product mix; when the analyst noted that negative mix should have pressured gross margin, management maintained margins vary product-to-product and declined to elaborate further.
- Intangible write-off breakup: The split of ₹29 cr in H1 write-offs between Q1 and Q2 was not provided beyond "major portion in Q1, hardly anything in Q2."
- Non-agrochemical volume vs margin paradox: Why volume growth exceeds sales growth for 3-4 quarters while margins improve drew "I'm not able to comment anything because we don't have all the so much detailed information offhand."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year EBITDA margin | 15% to 18% | FY26 |
| Full-year capex | ₹450 cr to ₹500 cr | FY26 |
| H2 vs H1 seasonality | Second half stronger than first half | FY26 |
| H2 gross margins | In similar range to H1 | H2 FY26 |
| US tariff impact | No substantial impact expected | H2 FY26 |
| Revenue crossing ₹5,000 cr | Confirmed as possible | FY26 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹929 cr, +20% YoY |
| Agrochemical revenue | ₹803 cr, +27% YoY |
| Non-agrochemical revenue | ₹126 cr, -11% YoY |
| Overall volume growth | 35% YoY |
| Agrochemical volume growth | 36% YoY |
| Gross margin | 34.5%, +690 bps YoY |
| EBITDA | ₹139 cr, +71% YoY |
| EBITDA margin | 15% |
| PAT | ₹74 cr, +75% YoY |
| FY26 EBITDA margin guidance | 15% to 18% for full year |
| Working capital days | 84 days, improvement of 34 days vs March 2025 |
| Cash, bank and liquid investments | ₹794 cr as on 30 September 2025 |
| Total product registrations | 2,994 as on 30 September 2025 |
| Registration applications at approval stage | 1,068 globally |
| ROCE | 21.6% as on 30 September 2025 |
| ROE | 17.5% as on 30 September 2025 |